多西他赛联合卡培他滨治疗晚期乳腺癌的疗效分析  

Effect analysis of docetaxel combined with capecitabine in the treatment of advanced breast cancer

作　　者：王玥玥 WANG Yue-yue(Department of Radiotherapy,Dandong First Hospital,Dandong 118000,China)

机构地区：[1]丹东市第一医院放疗科,118000

出　　处：《中国现代药物应用》2021年第15期167-169,共3页Chinese Journal of Modern Drug Application

摘　　要：目的探讨多西他赛联合卡培他滨治疗晚期乳腺癌的疗效。方法94例晚期乳腺癌患者,随机分为对照组和研究组,每组47例。对照组患者仅采用多西他赛治疗,研究组患者采用多西他赛联合卡培他滨治疗。比较两组患者血清癌胚抗原(CEA)、糖类抗原153(CA153)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)水平及临床疗效。结果研究组血清CEA、CA125、VEGF、MMP-9水平分别为(2.37±1.09)U/ml、(11.52±2.53)U/ml、(56.42±13.26)pg/ml、(33.17±6.37)ng/ml,明显低于对照组的(5.47±1.25)U/ml、(15.40±3.88)U/ml、(82.01±15.27)pg/ml、(43.72±9.17)ng/ml,差异具有统计学意义(P<0.05)。研究组总有效率及临床获益率分别为38.3%、89.4%,均明显高于对照组的19.1%、68.1%,差异具有统计学意义(P<0.05)。结论采用多西他赛联合卡培他滨化疗能够有效降低晚期乳腺癌患者的血清CEA、CA125、VEGF、MMP-9水平,提高临床疗效。Objective To discuss the efficacy of docetaxel combined with capecitabine in the treatment of advanced breast cancer.Methods A total of 94 patients with advanced breast cancer were randomly divided into control group and research group,with 47 cases in each group.The control group was treated with docetaxel,and the research group was treated with docetaxel combined with capecitabine.The serum carcinoembryonic antigen(CEA),carbohydrate antigen(CA153),vascular endothelial growth factor(VEGF)and matrix metalloproteinases-9(MMP-9),and clinical efficacy were compared between the two groups.Results The serum CEA,CA125,VEGF and MMP-9 of the research group were(2.37±1.09)U/ml,(11.52±2.53)U/ml,(56.42±13.26)ng/ml and(56.42±13.26)ng/ml,which were obviously lower than(5.47±1.25)U/ml,(15.40±3.88)U/ml,(82.01±15.27)ng/ml and(43.72±9.17)ng/ml of the control group,and the difference was statistically significant(P<0.05).The total effective rate and clinical benefit rate of the research group were 38.3% and 89.4%,which were obviously higher than 19.1% and 68.1% of the control group,and the difference was statistically significant(P<0.05).Conclusion Combined chemotherapy of docetaxel and capecitabine can effectively reduce serum CEA,CA125,VEGF and MMP-9 levels in patients with advanced breast cancer,and improve clinical efficacy.

关 键 词：多西他赛 卡培他滨 晚期乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]